Bluebird Bio Inc. (BLUE:NSD) Analysts rate as a Hold, $5.29 target

STA Research
by: STA Research
Bluebird stock forecast

Bluebird bio Inc Stock Analysis:

Based on the Bluebird bio Inc the stock forecasts from 7 analysts, the average analyst target price for Bluebird bio Inc is USD 5.29 over the next 12 months. Bluebird bio Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Bluebird bio Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Bluebird bio Inc’s stock price was USD 6.34Bluebird bio Inc’s stock price has changed by -11.20% over the past week, +9.12% over the past month and -65.39% over the last year.

Bluebird bio stock forecast from 10 Crowd analysts, has the average 12 month Crowd target price for Bluebird Bio Inc at USD 10.94 over the next 12 months. Bluebird bio Inc’s average Crowd rating is a Buy.


About Bluebird bio Inc (BLUE:NSD)

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company’s clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.


Most Recent Analyst Ratings for BLUE’s stock price:

Upgrades Barclays Equal-Weight USD 3 » USD 5 2022-08-05
Upgrades Raymond James Capital Outperform USD 8 2022-08-02
Maintains Goldman Sachs Sell USD 3 » USD 2 2022-05-24
Target Down Morgan Stanley Underweight USD 3 2022-05-17
Reiterated by Wedbush Neutral USD 10 » USD 8 2022-05-10
Target Lowered by Barclays USD 4 » USD 3 2022-05-10
Target Lowered SVB Leerink Market Perform USD 10 » USD 8 2022-04-06
Downgraded by Cowen Outperform » Market Perform 2022-04-06
Reiterated by Goldman Sachs Sell » Sell USD 9 » USD 3 2022-03-09
Maintains Wells Fargo Equal-Weight USD 12 » USD 8 2022-03-08
Downgrades Barclays Underweight USD 13 » USD 4 2022-03-07
Maintains SVB Leerink Market Perform USD 11 » USD 10 2022-03-07
Target Lowered Morgan Stanley Underweight USD 6 » USD 5 2022-03-07
Target Lowered  Morgan Stanley Underweight USD 11 » USD 10 2022-01-06
Upgraded by Goldman Sachs Buy » Conviction-Buy 2022-01-03
Reiterated by SVB Leerink Hold 2021-12-23
Target Lowered  BMO Financial Market Perform USD 21 » USD 13 2021-11-12
Reiterated by Berenberg Capital Markets Hold USD 11 2021-11-12
Downgraded by Morgan Stanley Equal Weight »
Underweight USD 11 2021-11-08
Target Lowered by Wells Fargo Equal Weight USD 25 » USD 16 2021-11-08
Target Lowered by Wedbush Neutral USD 22 » USD 11 2021-11-08
Target Lowered by RBC Royalbank Neutral » Sector Perform USD 26 » USD 14 2021-11-08
Target Lowered by Canaccord Capital Hold USD 20 » USD 15 2021-11-08
Downgraded by Goldman Sachs Neutral » Sell USD 23 » USD 10 2021-11-08
Target Lowered by Barclays Equal Weight USD 20 » USD 13 2021-11-08


The U.S. Food and Drug Administration (FDA) has approved SKYSONA® (elivaldogene autotemcel), also known as eli-cel, to slow the progression of neurologic dysfunction in boys between the ages of 4 and 17 who have early, active cerebral adrenoleukodystrophy. Bluebird Bio  declared that the clinical hold that had been placed on the eli-cel clinical development program had been lifted.


What we Don’t Like:

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What we don’t like:

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector



Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.

Leave a Reply

Your email address will not be published.